General Background Resolvins (resolution phase interaction products) are a new class of anti-inflammatory mediators derived from the ω 3 fatty acids eicosapentaenoate and docosahexaenoate. Those derived from : 5Z8Z11Z14Z17Z-EICOSAPENTAENOATE (EPA) are termed the E-series resolvins . These endogenous mediators have been found in leukocytes, brain and glial cells. These oxygenated derivatives function to halt leukocyte recruitment to sites of inflammation and facilitate resolution of the inflammatory process. The administration of aspirin during inflammation results in the production of the 18R series resolvins from eicosapentaenoate . Eicosapentaenoate derived resolvins E1 and E2 can also be formed by microbial cytochrome P450 monooxygenase independent of : CPD-524 . : CPD-524 "Aspirin" has well known anti-inflammatory and antipyretic functions. It also has an anti-clotting function through the inhibition of thromboxane synthesis, and is often prescribed long-term at low doses, to help prevent heart attacks, strokes, and blood clot formation in high risk patients. Aspirin may also prevent the occurrence of certain types of cancer. : CPD-524 "Aspirin" exerts its actions by the inhibition of both : HS01815-MONOMER "COX-1" and : HS01115-MONOMER "COX-2" which has a direct negative effect on prostaglandin synthesis. It irreversibly acetylates COX-2 which loses the ability to generate prostaglandin intermediates. However, COX-2 retains oxygenase activity which results in the production of anti-inflammatory mediators like resolvins. About this Pathway Aspirin mediated acetylation of COX-2 triggers the synthesis of the 18R series resolvins E1 and E2 from : 5Z8Z11Z14Z17Z-EICOSAPENTAENOATE. Resolvin E1 is 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoate . The enzyme : HS00336-MONOMER is pivotal in the catalysis of : CPD66-68 "18-HEPE to : CPD66-69 "5S,18-HEPE which leads to the downstream production of resolvins E1 and E2 . The enzyme : HS03372-MONOMER catalyzes the conversion of : CPD66-70 to : CPD66-57 . Resolvin E1 inhibits leukocyte transendothelial migration and IL-2 production . Resolvin E1 can prevent the development of inflammatory bowel disease in a mouse model, and may play a protective role in a number of disorders that involve inflammation . Resolvin E2 is produced in neutrophils and can inhibit neutrophil transmigration in vivo . The actions of resolvins are mediated by G-protein coupled receptors

external resources